13 citations
,
July 2019 in “Dermatologic therapy” Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
Female rats showed more panic-related behavior than males, influenced by hormonal cycles and certain drugs.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
4 citations
,
June 2013 in “The Journal of Rheumatology” The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
September 2025 in “Value in Health”
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
9 citations
,
January 2013 in “Indian journal of dermatology, venereology, and leprology” Infliximab may cause hair loss in Crohn's disease patients.
13 citations
,
January 1999 in “Postgraduate Medicine” New drugs for rheumatoid arthritis show improvement but have side effects and are not a cure.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
35 citations
,
February 2023 in “Biomolecules” Granzyme B is important in autoimmune skin diseases and could be a new treatment target.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
October 2025 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” 20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking CCR5 can prevent and improve hair loss in alopecia areata.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
January 2024 in “Pharmacoepidemiology” Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
10 citations
,
October 2018 in “Neurology Neuroimmunology & Neuroinflammation” Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.